de ProShare Advisors Pacific Biosciences PACB Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 79.3 k | Vender |
47,184
-6,351
| -12% | -USD 9.23 k | ﹤0.01% | 1802 |
|
|
2026
Q1 | USD 70.7 k | Vender |
53,535
-10,264
| -16% | -USD 18.4 k | ﹤0.01% | 1752 |
|
|
2025
Q4 | USD 119 k | Comprar |
63,799
+5,883
| +10% | +USD 11.3 k | ﹤0.01% | 1838 |
|
|
2025
Q3 | USD 74.1 k | Vender |
57,916
-9,912
| -15% | -USD 13.4 k | ﹤0.01% | 1886 |
|
|
2025
Q2 | USD 84.1 k | Vender |
67,828
-3,744
| -5% | -USD 4.32 k | ﹤0.01% | 1903 |
|
|
2025
Q1 | USD 84.5 k | Vender |
71,572
-18,436
| -20% | -USD 28.3 k | ﹤0.01% | 1872 |
|
|
2024
Q4 | USD 165 k | Comprar |
90,008
+22,215
| +33% | +USD 43.4 k | ﹤0.01% | 1945 |
|
|
2024
Q3 | USD 115 k | Comprar |
67,793
+17,216
| +34% | +USD 28.3 k | ﹤0.01% | 1855 |
|
|
2024
Q2 | USD 69.3 k | Vender |
50,577
-13,493
| -21% | -USD 27.2 k | ﹤0.01% | 1711 |
|
|
2024
Q1 | USD 240 k | Comprar |
64,070
+5,300
| +9% | +USD 31 k | ﹤0.01% | 1562 |
|
|
2023
Q4 | USD 577 k | Comprar |
58,770
+9,023
| +18% | +USD 73.8 k | ﹤0.01% | 962 |
|
|
2023
Q3 | USD 415 k | Comprar |
49,747
+84
| +0.2% | +USD 960 | ﹤0.01% | 1010 |
|
|
2023
Q2 | USD 661 k | Comprar |
49,663
+1,445
| +3% | +USD 17.6 k | ﹤0.01% | 838 |
|
|
2023
Q1 | USD 558 k | Comprar |
48,218
+437
| +0.9% | +USD 4.34 k | ﹤0.01% | 870 |
|
|
2022
Q4 | USD 391 k | Comprar |
47,781
+3,968
| +9% | +USD 34.2 k | ﹤0.01% | 1087 |
|
|
2022
Q3 | USD 254 k | Vender |
43,813
-2,716
| -6% | -USD 15.6 k | ﹤0.01% | 1244 |
|
|
2022
Q2 | USD 206 k | Vender |
46,529
-17,843
| -28% | -USD 108 k | ﹤0.01% | 1459 |
|
|
2022
Q1 | USD 586 k | Vender |
64,372
-14,651
| -19% | -USD 169 k | ﹤0.01% | 1179 |
|
|
2021
Q4 | USD 1.62 M | Comprar |
79,023
+6,876
| +10% | +USD 166 k | ﹤0.01% | 817 |
|
|
2021
Q3 | USD 1.84 M | Vender |
72,147
-13,949
| -16% | -USD 413 k | 0.01% | 731 |
|
|
2021
Q2 | USD 3.01 M | Comprar |
86,096
+10,662
| +14% | +USD 310 k | 0.01% | 630 |
|
|
2021
Q1 | USD 2.51 M | Comprar |
75,434
+7,367
| +11% | +USD 258 k | 0.01% | 630 |
|
|
2020
Q4 | USD 1.77 M | Comprar |
68,067
+19,125
| +39% | +USD 325 k | 0.01% | 667 |
|
|
2020
Q3 | USD 483 k | Comprar |
48,942
+4,547
| +10% | +USD 26.2 k | ﹤0.01% | 955 |
|
|
2020
Q2 | USD 153 k | Comprar |
44,395
+14,983
| +51% | +USD 51 k | ﹤0.01% | 1517 |
|
|
2020
Q1 | USD 90 k | Vender |
29,412
-22,977
| -44% | -USD 94.1 k | ﹤0.01% | 1087 |
|
|
2019
Q4 | USD 269 k | Vender |
52,389
-5,231
| -9% | -USD 26.6 k | ﹤0.01% | 1409 |
|
|
2019
Q3 | USD 297 k | Vender |
57,620
-1,584
| -3% | -USD 8.86 k | ﹤0.01% | 1239 |
|
|
2019
Q2 | USD 358 k | Vender |
59,204
-7,106
| -11% | -USD 49.8 k | ﹤0.01% | 1154 |
|
|
2019
Q1 | USD 479 k | Comprar |
66,310
+1,420
| +2% | +USD 10.3 k | ﹤0.01% | 1034 |
|
|
2018
Q4 | USD 480 k | Vender |
64,890
-3,819
| -6% | -USD 24.2 k | ﹤0.01% | 966 |
|
|
2018
Q3 | USD 372 k | Vender |
68,709
-2,757
| -4% | -USD 11.8 k | ﹤0.01% | 1246 |
|
|
2018
Q2 | USD 254 k | Vender |
71,466
-3,716
| -5% | -USD 10.3 k | ﹤0.01% | 1480 |
|
|
2018
Q1 | USD 154 k | Vender |
75,182
-2,831
| -4% | -USD 7.35 k | ﹤0.01% | 1590 |
|
|
2017
Q4 | USD 206 k | Comprar |
78,013
+5,784
| +8% | +USD 20.3 k | ﹤0.01% | 1624 |
|
|
2017
Q3 | USD 379 k | Comprar |
72,229
+16,798
| +30% | +USD 72.2 k | ﹤0.01% | 1065 |
|
|
2017
Q2 | USD 197 k | Vender |
55,431
-3,263
| -6% | -USD 13.2 k | ﹤0.01% | 1352 |
|
|
2017
Q1 | USD 303 k | Vender |
58,694
-15,413
| -21% | -USD 75.4 k | ﹤0.01% | 1244 |
|
|
2016
Q4 | USD 282 k | Comprar |
74,107
+8,300
| +13% | +USD 60.3 k | ﹤0.01% | 1405 |
|
|
2016
Q3 | USD 590 k | Vender |
65,807
-8,399
| -11% | -USD 70.2 k | 0.01% | 888 |
|
|
2016
Q2 | USD 522 k | Comprar |
74,206
+7,057
| +11% | +USD 64.5 k | 0.01% | 950 |
|
|
2016
Q1 | USD 571 k | Vender |
67,149
-3,625
| -5% | -USD 35.7 k | 0.01% | 938 |
|
|
2015
Q4 | USD 929 k | Comprar |
70,774
+7,814
| +12% | +USD 70.1 k | 0.01% | 768 |
|
|
2015
Q3 | USD 230 k | Vender |
62,960
-4,262
| -6% | -USD 20.8 k | ﹤0.01% | 1251 |
|
|
2015
Q2 | USD 387 k | Vender |
67,222
-3,451
| -5% | -USD 20 k | 0.01% | 1204 |
|
|
2015
Q1 | USD 413 k | Comprar |
70,673
+11,065
| +19% | +USD 76.3 k | ﹤0.01% | 1280 |
|
|
2014
Q4 | USD 467 k | Comprar |
59,608
+371
| +0.6% | +USD 2.37 k | 0.01% | 1237 |
|
|
2014
Q3 | USD 291 k | Vender |
59,237
-11,589
| -16% | -USD 60.6 k | ﹤0.01% | 1740 |
|
|
2014
Q2 | USD 438 k | Vender |
70,826
-28,272
| -29% | -USD 141 k | 0.01% | 1668 |
|
|
2014
Q1 | USD 530 k | Comprar |
99,098
+66,400
| +203% | +USD 420 k | 0.01% | 1824 |
|
|
2013
Q4 | USD 171 k | Vender |
32,698
-20,595
| -39% | -USD 94.6 k | ﹤0.01% | 1269 |
|
|
2013
Q3 | USD 295 k | Comprar |
53,293
+15,523
| +41% | +USD 53.9 k | 0.01% | 1912 |
|
|
2013
Q2 | USD 95 k | Comprar |
+37,770
| Nuevas | +USD 94 k | ﹤0.01% | 2269 |
|
Otros fondos que tienen PACB en su cartera
Posición de ProShare Advisors en PACB: resumen de T2 2026
ProShare Advisors redujo su participación en Pacific Biosciences (PACB) en 12% durante T2 2026, al vender acciones por un valor estimado de USD 9.23 k, y conservó 47,184 acciones valuadas en USD 79.3 k. La posición representa ﹤0.01% de la cartera y ocupa el puesto #1802.
ProShare Advisors reportó por primera vez una posición en PACB en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. La posición alcanzó su máximo de USD 3.01 M en T2 2021. Al cierre de T2 2026, 223 fondos que sigue Wall St. Rank mantienen una posición en PACB.
- Al cierre de T2 2026, ProShare Advisors tenía 47,184 acciones de Pacific Biosciences con un valor de USD 79.3 k.
- ProShare Advisors vendió 6,351 acciones de Pacific Biosciences en T2 2026, por un valor estimado de USD 9.23 k.
- Pacific Biosciences representó ﹤0.01% de la cartera de ProShare Advisors en T2 2026 y fue su posición número 1802.
- ProShare Advisors reportó por primera vez una posición en Pacific Biosciences en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- La posición de ProShare Advisors en Pacific Biosciences alcanzó su máximo de USD 3.01 M en T2 2021.
- Al cierre de T2 2026, 223 fondos que sigue Wall St. Rank tenían Pacific Biosciences en cartera.
Según el Informe 13F de ProShare Advisors correspondiente a T2 2026, presentado el 11 ago 2026.